Clinical trial
Evaluation of DHA for the Treatment of PSC
NCT00325013 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00325013 |
|---|---|
| Title | Evaluation of DHA for the Treatment of PSC |
| Official title | Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC) |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Primary Sclerosing Cholangitis, Colitis |
| Intervention type | Drug |
| Interventions | Docosahexaenoic Acid (DHA) |
| Enrollment | 10 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | May 11, 2006 |
| Last update posted | Mar 11, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: